Precision Biosciences Inc (DTIL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Precision Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Precision Biosciences Inc's ROI in the second quarter of 2026?
Precision Biosciences Inc recorded a cumulative net loss of $-53 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -47.27%.
Within the Healthcare sector 238 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2134 to 3563.
Precision BioSciences: Navigating Challenges and Achievements in the Gene Editing Landscape Precision BioSciences, Inc. a clinical-stage gene editing company based in Durham, North Carolina, continues to make strides in the biotechnology sector, notably through its proprietary ARCUS platform. The company recently released its financial results for the third quarter of 2024, revealing both progress and setbacks as it navigates the complexities of advancing its in vivo gene editing therapies. Financial Performance Overview In Q3 2024, Precision BioSciences reported a return on average invested assets (ROI) of 6.44%. This figure stands in stark contrast to the company s average ROI of -37.95%, indicative of a challenging investment landscape. However, the recent ROI reflects a notable decline from previous performance, driven in part by a decrease in net income.
Revolutionizing Gene Editing: Precision BioSciences Strategic Advances in Viral Hepatitis and Oncology Precision BioSciences Inc. a key player in the advanced gene editing sphere, is gearing up for significant milestones in its journey towards transforming therapeutic landscapes. Through its pioneering ARCUS technology, the company is setting the stage for novel interventions in viral hepatitis and oncology, promising groundbreaking therapeutic strategies that leverage sophisticated gene edits such as elimination, insertion, and excision. Fireside Chat at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference In the dynamic sphere of viral hepatitis treatments, Precision BioSciences is poised to share its revolutionary insights at the upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. Scheduled for October 8, 2024, at 11:00 A.M. ET, this event promises to illuminate the substantial potential of ARCUS technology in crafting targeted in vivo gene editing therapies. This is not just a presentation; it is a beacon of promise for those affected by viral hepatitis, showcasing how gene editing platforms can redefine therapeutic interventions.
In the rapidly evolving landscape of modern medicine, the pursuit of innovative therapies for chronic viral infections has reached a critical juncture. Precision BioSciences, Inc. (NASDAQ: DTIL), a pioneer in the field of gene editing, has recently taken a significant step forward in this domain. The Durham, North Carolina-based company has submitted Clinical Trial Applications (CTAs) to commence Phase 1 clinical trials for its groundbreaking in vivo gene editing program, PBGENE-HBV. This initiative aims to address the urgent and unmet medical need for a curative treatment for chronic hepatitis B virus (HBV) infection, which currently affects hundreds of millions of individuals worldwide. The Significance of PBGENE-HBV Chronic hepatitis B remains a major public health challenge, often leading to severe liver disease, including cirrhosis and hepatocellular carcinoma. While antiviral therapies have made strides in managing the virus, they typically do not eliminate it from the body. The underlying goal of PBGENE-HBV is to harness the power of gene editing to achieve a functional cure for this persistent infection. By utilizing Precision BioSciences proprietary ARCUS platform, the company aims to facilitate precise genomic edits that could permanently eliminate HBV DNA from infected liver cells, thereby disrupting viral replication and potentially restoring normal liver function.
Financial Statements
Precision Biosciences Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
